Results 51 to 60 of about 4,200 (201)

New class of agents for treatment of hypertension: Focus on direct renin inhibition

Vascular Health and Risk Management, 2010
Roberto Fogari, Annalisa ZoppiDepartment of Internal Medicine and Therapeutics, University of Pavia, ItalyAbstract: Aliskiren, the first orally active direct renin inhibitor, is an effective antihypertensive drug with distinctive characteristics ...
Roberto Fogari, Annalisa Zoppi
doaj  

Direct Renin Inhibition with Aliskiren Improves Ischemia-Induced Neovasculogenesis in Diabetic Animals via the SDF-1 Related Mechanism.

PLoS ONE, 2015
ObjectiveAliskiren is a direct renin inhibitor which is suggested to modify proangiogenic cells in addition to lower blood pressure. Given that angiogenesis is impaired in the presence of diabetes mellitus, we would like to investigate whether and how ...
Ting-Ting Chang, Tao-Cheng Wu, Po-Hsun Huang, Chih-Pei Lin, Jia-Shiong Chen, Liang-Yu Lin, Shing-Jong Lin, Jaw-Wen Chen   +7 more
doaj   +1 more source

Aliskiren versus ramipril in hypertension

, 2010
Aliskiren is an orally active direct renin inhibitor which inhibits the synthesis of angiotensin I by linking to active renin on a deep cleft of its molecular structure, the site of hydrolysis of the Leu10-Val11 bond of angiotensinogen.
G. Mazzotta, GENTILE, GIORGIO, Mazzotta G, P. Martire, Garofoli M, Martire P, Gentile G, P. Verdecchia, Angeli F, M. Garofoli, REBOLDI, Gianpaolo, Reboldi G, ANGELI, FABIO, Verdecchia P, Paola Martire, Fabio Angeli, Gianpaolo Reboldi, Marta Garofoli, Giorgio Gentile, Paolo Verdecchia, Giovanni Mazzotta   +20 more
core   +1 more source

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors [PDF]

, 2009
The renin-angiotensin-aldosterone system (RAAS) is an important mediator of blood pressure (BP) and volume regulation in both normotensive and hypertensive persons and is a major contributor to hypertension-related target organ damage.
Oparil, Suzanne, Pimenta, Eduardo, Eduardo Pimenta, Suzanne Oparil   +3 more
core   +1 more source

Effects of Paricalcitol and Aliskiren Combination Therapy on Experimental Diabetic Nephropathy Model in Rats

Kidney & Blood Pressure Research, 2014
Background/Aims: The aim of the present study was to investigate the effect of combination of aliskiren with paricalcitol on experimental diabetic nephropathy (DN) model in rats.
Zehra Eren, Mehmet Yalçin Günal, Elif Arı Bakir, Jale Coban, Berrak Çağlayan, Nur Ekimci, Sinem Ethemoglu, Ozgur Albayrak, Tuba Akdeniz, Gülderen Yanikkaya Demirel, Ertuğrul Kiliç, Gülçin Kantarci   +11 more
doaj   +1 more source

Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor

Therapeutics and Clinical Risk Management, 2011
Ayad K AliDepartment of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL, USABackground: The purpose of this study was to examine the postmarketing safety profile of aliskiren hemifumarate, a first-in-class ...
Ali AK
doaj  

The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy--a randomized cross-over study.

PLoS ONE, 2013
BackgroundLaboratory research and previous study suggest that aliskiren, a direct renin inhibitor, has anti-proteinuric effects. We conducted a randomized crossover study to evaluate the anti-proteinuric effect of aliskiren in patients with ...
Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, Chi-Bon Leung, Philip Kam-Tao Li   +4 more
doaj   +1 more source

Effects of Aliskiren, an RAAS inhibitor, on a carrageenan-induced pleurisy model of rats

Anais da Academia Brasileira de Ciências, 2018
Our aim is to investigate the potentially preventive effects of Aliskiren in a carrageenan-induced lung pleurisy model and to compare the standard anti-inflammatory agents, indomethacin and dexamethasone.
YASIN BAYIR, HARUN UN, ELIF CADIRCI, EROL AKPINAR, BUSRA DIYARBAKIR, ILKNUR CALIK, ZEKAI HALICI   +6 more
doaj   +1 more source

Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome

Diabetology & Metabolic Syndrome, 2017
Background Non-alcoholic steatohepatitis (NASH) is highly associated with metabolic syndrome, a major cause of morbidity in the globalized society. The renin–angiotensin system (RAS) influences hepatic fatty acid metabolism, inflammation and fibrosis ...
F. N. Ramalho, S. C. Sanches, M. C. Foss, M. J. Augusto, D. M. Silva, A. M. Oliveira, L. N. Ramalho   +6 more
doaj   +1 more source

Physiologically‐Based Pharmacokinetic Modeling to Support Pediatric Clinical Development: An IQ Working Group Perspective on the Current Status and Challenges

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Pediatric extrapolation strategies issued by health authorities have streamlined pediatric drug development and reduced the unnecessary burden of conducting pediatric clinical studies. In line with these strategies, physiologically based pharmacokinetic (PBPK) models have been utilized extensively for initial dosing regimen and sampling ...
James W. T. Yates, Michael Zientek, Kunal S. Taskar, Wen Lin, Tycho Heimbach, Stefan Willmann, Jessica Rehmel, Neil Parrott, Michael Hanley, Justine Badee, Yuan Chen, Susan Cole, Loeckie De Zwart, Sebastian Haertter, Rongrong Jiang, Masakatsu Kotsuma, Guiqing Liang, Yu‐Wei Lin, Jing Liu, Ying Ou, Juliane Rascher, Naveed A. Shaik, Jan Wahlstrom, Xiaofeng Wang, Guangqing Xiao, Ka Lai Yee, S. Y. Amy Cheung   +26 more
wiley   +1 more source